<p>Y Intercept Hong Kong Ltd 在第三季度购买了 Glaukos Corporation (NYSE:GKOS - 免费报告) 的新股份，根据该公司在最近向证券交易委员会提交的文件。该公司购买了 11,479 股医疗器械供应商的股票，价值约 936,000 美元。</p>
<p>其他机构投资者最近也增加或减少了在该公司的股份。Smartleaf Asset Management LLC 在第二季度将其在 Glaukos 的持股增加了 16.2%。Smartleaf Asset Management LLC 目前拥有 973 股医疗器械供应商的股票，价值 99,000 美元，此前在该期间内购买了额外的 136 股。AQR Capital Management LLC 在第一季度将其在 Glaukos 的持股增加了 2.6%。AQR Capital Management LLC 目前拥有 7,788 股医疗器械供应商的股票，价值 766,000 美元，此前在上个季度购买了额外的 198 股。Amalgamated Bank 在第三季度将其在 Glaukos 的持股增加了 1.5%。Amalgamated Bank 目前拥有 16,238 股医疗器械供应商的股票，价值 1,324,000 美元，此前在该期间内购买了额外的 242 股。Profund Advisors LLC 在第二季度将其在 Glaukos 的持股增加了 13.9%。Profund Advisors LLC 目前拥有 2,822 股医疗器械供应商的股票，价值 291,000 美元，此前在该期间内购买了额外的 345 股。最后，加利福尼亚州教师退休系统在第二季度将其在 Glaukos 的持股增加了 0.8%。加利福尼亚州教师退休系统目前拥有 50,854 股医疗器械供应商的股票，价值 5,253,000 美元，此前在上个季度购买了额外的 421 股。对冲基金和其他机构投资者拥有该公司 99.04% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<p>几家研究公司最近对 GKOS 发布了报告。富国银行将 Glaukos 的股票目标价从 120.00 美元提高至 122.00 美元，并在 10 月 30 日的研究报告中给予该股票 &#34;超配&#34; 评级。Piper Sandler 重申了 &#34;超配&#34; 评级，并在 1 月 14 日的报告中对 Glaukos 的股票设定了 165.00 美元的目标价。花旗集团将 Glaukos 的目标价从 113.00 美元提高至 125.00 美元，并在 12 月 11 日的研究报告中给予该公司 &#34;买入&#34; 评级。Stephens 将 Glaukos 的目标价从 115.00 美元提高至 145.00 美元，并在 1 月 2 日的研究报告中给予该股票 &#34;超配&#34; 评级。最后，Stifel Nicolaus 将 Glaukos 的目标价从 115.00 美元提高至 160.00 美元，并在 1 月 22 日的研究报告中给予该公司 &#34;买入&#34; 评级。一位投资分析师对该股票给予了强烈买入评级，十二位给予了买入评级，一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，Glaukos 目前的平均评级为 &#34;适度买入&#34;，平均目标价为 132.54 美元。</p>
<p><strong>查看我们关于 Glaukos 的最新报告</strong></p>
<h2>Glaukos 的内部活动</h2>
<p>在其他 Glaukos 的新闻中，董事 Marc Stapley 于 1 月 22 日星期四出售了 15,000 股公司的股票。该股票以平均价格 127.71 美元出售，总价值为 1,915,650.00 美元。交易后，该董事直接持有 37,449 股公司的股票，价值 4,782,611.79 美元。这代表其持股减少了 28.60%。该出售在向 SEC 提交的文件中披露，相关文件可在 SEC 网站上获取。此外，首席财务官 Alex R. Thurman 于 11 月 25 日星期二出售了 315 股公司的股票。该股票以平均价格 105.00 美元出售，总交易额为 33,075.00 美元。出售后，首席财务官直接持有 50,488 股公司的股票，价值 5,301,240 美元。该交易使其持股减少了 0.62%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士在过去九十天内出售了价值 37,752,234 美元的 329,655 股公司股票。公司内部人士持有公司 6.40% 的股票。</p>
<h2>Glaukos 股票表现</h2>
<p>NYSE:GKOS 周一开盘价为 119.68 美元。该公司有 50 天的移动平均线为 113.22 美元，200 天的移动平均线为 96.83 美元。公司的债务与股本比率为 0.09，流动比率为 5.20，速动比率为 4.47。该股票的市值为 68.7 亿美元，市盈率为 -77.72，贝塔值为 0.70。Glaukos Corporation 的 1 年低点为 73.16 美元，1 年高点为 161.78 美元。</p>
<h2>Glaukos 公司简介</h2>
<p>(免费报告)</p>
<p>Glaukos Corporation 是一家医疗技术公司，专注于开发、制造和商业化创新疗法，以治疗青光眼和其他慢性眼病。公司的核心产品专注于微创青光眼手术 (MIGS)，旨在比传统手术方法更安全有效地降低眼内压并管理青光眼。Glaukos 的旗舰产品包括 iStent、iStent inject 和 iStent infinite 小梁微旁路支架，这些支架在白内障手术中植入，以改善房水流出并帮助控制眼压。</p>
<p>除了 MIGS 产品组合，Glaukos 还扩展到了持续药物输送解决方案。</p>
<h2>精选文章</h2>
<ul>
<li>我们更喜欢的五只股票比 Glaukos 更好</li>
<li>特朗普刚刚签署了它</li>
<li>警报：在明天市场开盘前抛售这五只股票！</li>
<li>黄金警报</li>
<li>特朗普的最后震惊行动将于 2 月 24 日开始</li>
<li>什么费用可以从资本利得税中扣除？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdLT1M?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdLT1M"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Glaukos 吗？</h2>
<p>在考虑 Glaukos 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Glaukos 并不在名单上。</p>
<p>虽然 Glaukos 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

GKOS

<p>Y Intercept Hong Kong Ltd 在第三季度收购了 11,479 股 Glaukos Corporation（纽约证券交易所代码：GKOS），价值约为 936,000 美元。其他机构投资者也调整了他们在 Glaukos 的持股。分析师们给予了积极的评级，目标价格范围在 122.00 美元到 165.00 美元之间。内部交易方面，董事 Marc Stapley 和首席财务官 Alex R. Thurman 进行了大量出售。Glaukos 股票开盘价为 119.68 美元，市值为 68.7 亿美元，市盈率为-77.72。在过去一年中，该股票的最低价为 73.16 美元，最高价为 161.78 美元</p>

<p>Y Intercept Hong Kong Ltd bought a new stake in Glaukos Corporation (NYSE:GKOS - Free Report) during the third quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The firm bought 11,479 shares of the medical instruments supplier's stock, valued at approximately $936,000.</p>
<div class="lb-trans"><p>Y Intercept Hong Kong Ltd 在第三季度购买了 Glaukos Corporation (NYSE:GKOS - 免费报告) 的新股份，根据该公司在最近向证券交易委员会提交的文件。该公司购买了 11,479 股医疗器械供应商的股票，价值约 936,000 美元。</p>
</div><p>Other institutional investors have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC raised its holdings in shares of Glaukos by 16.2% in the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier's stock worth $99,000 after purchasing an additional 136 shares during the period. AQR Capital Management LLC increased its position in Glaukos by 2.6% during the 1st quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier's stock worth $766,000 after purchasing an additional 198 shares in the last quarter. Amalgamated Bank raised its holdings in Glaukos by 1.5% in the third quarter. Amalgamated Bank now owns 16,238 shares of the medical instruments supplier's stock valued at $1,324,000 after buying an additional 242 shares during the period. Profund Advisors LLC raised its holdings in Glaukos by 13.9% in the second quarter. Profund Advisors LLC now owns 2,822 shares of the medical instruments supplier's stock valued at $291,000 after buying an additional 345 shares during the period. Finally, California State Teachers Retirement System lifted its position in Glaukos by 0.8% during the second quarter. California State Teachers Retirement System now owns 50,854 shares of the medical instruments supplier's stock valued at $5,253,000 after buying an additional 421 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者最近也增加或减少了在该公司的股份。Smartleaf Asset Management LLC 在第二季度将其在 Glaukos 的持股增加了 16.2%。Smartleaf Asset Management LLC 目前拥有 973 股医疗器械供应商的股票，价值 99,000 美元，此前在该期间内购买了额外的 136 股。AQR Capital Management LLC 在第一季度将其在 Glaukos 的持股增加了 2.6%。AQR Capital Management LLC 目前拥有 7,788 股医疗器械供应商的股票，价值 766,000 美元，此前在上个季度购买了额外的 198 股。Amalgamated Bank 在第三季度将其在 Glaukos 的持股增加了 1.5%。Amalgamated Bank 目前拥有 16,238 股医疗器械供应商的股票，价值 1,324,000 美元，此前在该期间内购买了额外的 242 股。Profund Advisors LLC 在第二季度将其在 Glaukos 的持股增加了 13.9%。Profund Advisors LLC 目前拥有 2,822 股医疗器械供应商的股票，价值 291,000 美元，此前在该期间内购买了额外的 345 股。最后，加利福尼亚州教师退休系统在第二季度将其在 Glaukos 的持股增加了 0.8%。加利福尼亚州教师退休系统目前拥有 50,854 股医疗器械供应商的股票，价值 5,253,000 美元，此前在上个季度购买了额外的 421 股。对冲基金和其他机构投资者拥有该公司 99.04% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several research firms have recently issued reports on GKOS. Wells Fargo &amp; Company increased their price objective on shares of Glaukos from $120.00 to $122.00 and gave the stock an &#34;overweight&#34; rating in a research report on Thursday, October 30th. Piper Sandler reiterated an &#34;overweight&#34; rating and issued a $165.00 price target on shares of Glaukos in a report on Wednesday, January 14th. Citigroup raised their price objective on Glaukos from $113.00 to $125.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, December 11th. Stephens boosted their price objective on Glaukos from $115.00 to $145.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, January 2nd. Finally, Stifel Nicolaus increased their target price on Glaukos from $115.00 to $160.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Glaukos currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $132.54.</p>
<div class="lb-trans"><p>几家研究公司最近对 GKOS 发布了报告。富国银行将 Glaukos 的股票目标价从 120.00 美元提高至 122.00 美元，并在 10 月 30 日的研究报告中给予该股票 &#34;超配&#34; 评级。Piper Sandler 重申了 &#34;超配&#34; 评级，并在 1 月 14 日的报告中对 Glaukos 的股票设定了 165.00 美元的目标价。花旗集团将 Glaukos 的目标价从 113.00 美元提高至 125.00 美元，并在 12 月 11 日的研究报告中给予该公司 &#34;买入&#34; 评级。Stephens 将 Glaukos 的目标价从 115.00 美元提高至 145.00 美元，并在 1 月 2 日的研究报告中给予该股票 &#34;超配&#34; 评级。最后，Stifel Nicolaus 将 Glaukos 的目标价从 115.00 美元提高至 160.00 美元，并在 1 月 22 日的研究报告中给予该公司 &#34;买入&#34; 评级。一位投资分析师对该股票给予了强烈买入评级，十二位给予了买入评级，一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，Glaukos 目前的平均评级为 &#34;适度买入&#34;，平均目标价为 132.54 美元。</p>
</div><p><strong>Check Out Our Latest Report on Glaukos</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Glaukos 的最新报告</strong></p>
</div><h2>Insider Activity at Glaukos</h2>
<div class="lb-trans"><h2>Glaukos 的内部活动</h2>
</div><p>In other Glaukos news, Director Marc Stapley sold 15,000 shares of the company's stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $127.71, for a total value of $1,915,650.00. Following the transaction, the director directly owned 37,449 shares of the company's stock, valued at $4,782,611.79. This represents a 28.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Alex R. Thurman sold 315 shares of the firm's stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $105.00, for a total transaction of $33,075.00. Following the sale, the chief financial officer directly owned 50,488 shares of the company's stock, valued at $5,301,240. The trade was a 0.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 329,655 shares of company stock worth $37,752,234 over the last ninety days. Company insiders own 6.40% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Glaukos 的新闻中，董事 Marc Stapley 于 1 月 22 日星期四出售了 15,000 股公司的股票。该股票以平均价格 127.71 美元出售，总价值为 1,915,650.00 美元。交易后，该董事直接持有 37,449 股公司的股票，价值 4,782,611.79 美元。这代表其持股减少了 28.60%。该出售在向 SEC 提交的文件中披露，相关文件可在 SEC 网站上获取。此外，首席财务官 Alex R. Thurman 于 11 月 25 日星期二出售了 315 股公司的股票。该股票以平均价格 105.00 美元出售，总交易额为 33,075.00 美元。出售后，首席财务官直接持有 50,488 股公司的股票，价值 5,301,240 美元。该交易使其持股减少了 0.62%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士在过去九十天内出售了价值 37,752,234 美元的 329,655 股公司股票。公司内部人士持有公司 6.40% 的股票。</p>
</div><h2>Glaukos Stock Performance</h2>
<div class="lb-trans"><h2>Glaukos 股票表现</h2>
</div><p>NYSE:GKOS opened at $119.68 on Monday. The firm has a 50-day moving average of $113.22 and a two-hundred day moving average of $96.83. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47. The stock has a market cap of $6.87 billion, a P/E ratio of -77.72 and a beta of 0.70. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $161.78.</p>
<div class="lb-trans"><p>NYSE:GKOS 周一开盘价为 119.68 美元。该公司有 50 天的移动平均线为 113.22 美元，200 天的移动平均线为 96.83 美元。公司的债务与股本比率为 0.09，流动比率为 5.20，速动比率为 4.47。该股票的市值为 68.7 亿美元，市盈率为 -77.72，贝塔值为 0.70。Glaukos Corporation 的 1 年低点为 73.16 美元，1 年高点为 161.78 美元。</p>
</div><h2>Glaukos Profile</h2>
<div class="lb-trans"><h2>Glaukos 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.</p>
<div class="lb-trans"><p>Glaukos Corporation 是一家医疗技术公司，专注于开发、制造和商业化创新疗法，以治疗青光眼和其他慢性眼病。公司的核心产品专注于微创青光眼手术 (MIGS)，旨在比传统手术方法更安全有效地降低眼内压并管理青光眼。Glaukos 的旗舰产品包括 iStent、iStent inject 和 iStent infinite 小梁微旁路支架，这些支架在白内障手术中植入，以改善房水流出并帮助控制眼压。</p>
</div><p>Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.</p>
<div class="lb-trans"><p>除了 MIGS 产品组合，Glaukos 还扩展到了持续药物输送解决方案。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Glaukos</li>
<li>Trump just signed it</li>
<li>ALERT: Drop these 5 stocks before the market opens tomorrow!</li>
<li>GOLD ALERT</li>
<li>Trump’s Final Shocking Act Begins February 24</li>
<li>What Expenses Can Be Deducted From Capital Gains Tax?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票比 Glaukos 更好</li>
<li>特朗普刚刚签署了它</li>
<li>警报：在明天市场开盘前抛售这五只股票！</li>
<li>黄金警报</li>
<li>特朗普的最后震惊行动将于 2 月 24 日开始</li>
<li>什么费用可以从资本利得税中扣除？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdLT1M" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=GKOS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Glaukos Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Glaukos 吗？</h2>
</div><p>Before you consider Glaukos, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Glaukos 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Glaukos 并不在名单上。</p>
</div><p>While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Glaukos 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Y Intercept Hong Kong Ltd 购入了 11,479 股 Glaukos Corporation $GKOS 的股票